Objective: The purpose of this study was to review the management of anesthesia for transapical transcatheter aortic valve implantation.
A
ORTIC STENOSIS (AS) is the most frequent acquired heart valve disease. More than 11,000 patients are treated in Germany annually and receive aortic valve replacement. 1 Conventional aortic valve replacement (AVR) with cardiopulmonary bypass (CPB) is the gold standard and has yielded excellent results.
In line with increasing patient age, anesthesiologists, cardiologists, and surgeons are confronted with elderly patients and more comorbidities. The risk of surgery may be higher in these elderly patients with significant comorbidities, 2 including compromised left ventricular function, pulmonary hypertension, severe respiratory dysfunction, renal insufficiency, general atherosclerosis, and possible neurologic dysfunction. All these comorbidities may affect the perioperative outcome. For these reasons, it is necessary to further develop minimally invasive therapeutic options in order to minimize perioperative trauma and improve postoperative patient outcome. Truly minimally invasive aortic valve therapy may be accomplished by using transcatheter approaches that avoid sternotomy and allow valve implantation on a beating heart, making CPB unnecessary. Recent clinical studies have proven the feasibility of minimally invasive aortic valve implantation (AVI), [3] [4] [5] [6] even in redo aortic valve surgery. 7 The European Association of Cardiothoracic Surgery and the European Society of Cardiology, in collaboration with the European Association of Percutaneous Cardiovascular Interventions, published a position statement saying that transcatheter AVI techniques should be restricted to high-risk patients or those with contraindications for surgery. 8 However, these new techniques can be implemented safely into routine clinical practice only when specific perioperative management issues are considered. 9, 10 Specifically, these new procedures will require alterations in the management of anesthesia. 11, 12 The aim of this retrospective study was to describe the anesthetic management for transcatheter transapical AVI (TA-AVI).
METHODS
The study was performed in accordance with the principles outlined in the Declaration of Helsinki and was approved by the local ethics board. This study was limited only to high surgical risk patients (age Ն75 years and numeric EuroSCORE Ն9 points). Additional inclusion criteria included an echocardiographically measured aortic annulus diameter of Յ24 mm and symmetric calcification of the 3 aortic valve cusps.
TA-AVI was performed in high-risk patients as described previously. 3 Under general anesthesia, femoral venous and arterial wires were placed percutaneously to allow the initiation of CPB if required. A left anterolateral minithoracotomy was performed in the 5th intercostal space with vertical incision of the pericardium. Apical pursestring sutures were used for antegrade and direct transcatheter access to the aortic valve. The minithoracotomy incision was 5 to 6 cm long. An epicardial pacing wire was placed by the surgeon. This pacing wire was used subsequently for rapid ventricular pacing (RVP) during balloon valvuloplasty and valve implantation. With the heart beating, the apex of the left ventricle was punctured, a soft guidewire was passed, and a soft 14F sheath was inserted. This was followed by insertion of a stiffer guidewire that was positioned across the aortic arch and anchored in the descending aorta. The sheath was partially withdrawn, and a 20-mm balloon valvuloplasty catheter was positioned under fluoroscopic and echocardiographic guidance. Balloon valvuloplasty was performed under RVP, with all patients receiving the same size balloon. The balloon catheter and apical sheath were then withdrawn, and a 33F transapical delivery sheath was inserted bluntly. This was followed by the valve, which was contained within its application system. After careful deairing, the valve was positioned so that the annulus bisected the stent under transesophageal echocardiographic (TEE) and fluoroscopic guidance. Correct valve position was confirmed by single-shot aortic root angiography and TEE. During a second brief episode of RVP, the valve was instantaneously implanted after rapid inflation of the balloon. The implantation sheath and guidewire were retrieved, and the apex and chest wall incisions were closed in a routine fashion.
The TA-AVI was performed under general anesthesia. All patients were treated according to the Leipzig fast-track protocol. 13 This consisted of oral premedication with dipotassium clorazepate the evening before surgery and midazolam on the day of surgery. Anesthetic induction of all patients was performed with bolus doses of propofol, sufentanil, and rocuronium. Anesthesia was maintained with sevoflurane and a continuous infusion of remifentanil. All patients were intubated orally with a single-lumen endotracheal tube (Mallinckrodt, Hennef/Sieg, Germany). Routine intraoperative ventilation was accomplished using a Zeus respirator (Draeger Medizintechnik AG, Luebeck, Germany). Hemodynamic monitoring consisted of a 12-lead electrocardiogram, pulse oximetry, an invasive arterial blood pressure (left radial), and central venous pressure (right jugular vein). All patients had external defibrillator pads placed (Quick-Combo REDI-PAK; PhysioControl Medtronic, Minneapolis, MN). The patients were supine with slight right lateral tilt. Blood transfusion was started if the hematocrit was lower than 25%. In case of bleeding, a cell saver was used for blood conservation.
The main anesthesia challenges of the procedure are as follows:
• Preparation for emergency CPB: in every patient, femoral venous and arterial wires were placed to initiate emergency CPB. 14 Heparin (100 IU/kg) was given to achieve an activated coagulation time Ͼ200 seconds.
• Avoidance of passive hypothermia: an external convective warming system with an underbody blanket (Bairhugger; Arizant Healthcare; Eden Prairie, MN) and an intravenous fluid heater system (Hotline; Smith Medical, Grasbrunn, Germany) were used to preserve a core temperature of 36°C.
• Hemodynamic and volume management: all patients received 500 mL of crystalloid infusion before starting the induction. The authors maintained the central venous pressure (CVP) above 10 cmH 2 O by volume substitution with crystalloids or colloids. The volume status and left ventricular function were monitored by TEE in the transgastric short-axis view, and the ejection fraction was calculated from measurements in the midesophageal 4-chamber view in the pre-and postsurgical TEE evaluation. During the entire procedure, the mean arterial pressure (MAP) was maintained above 65 mmHg. Intraoperative hypotension (MAP Ͻ 65 mmHg) was treated with intravenous crystalloid and/or colloid infusion and boluses of inotropic agents. Based on the findings of the left ventricular function on the TEE, the authors used 5-g norepinephrine boluses in patients with no regional wall motion abnormalities (RWMAs). In patients with any RWMAs or impaired left ventricular function (ejection fraction Ͻ45%), 5-g epinephrine boluses were used to increase the MAP Ͼ65 mmHg. Continuous infusion of inotropic agents was started whenever more than 4 boluses of inotropes were required to maintain the MAP. The authors increased the MAP to Ͼ75 mmHg after the apex puncturing of the heart in order to prevent hemodynamic deterioration after cessation of RVP. To achieve this MAP, 5-g 
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boluses of inotropes were given, or, in case of a continuous infusion, the rate was increased.
• RVP: the rapid pacing was started by the anesthesiologist with a frequency of 180 beats/min. Only when reliable capture was associated with a marked reduction in blood pressure was the balloon inflated. A reduction of systolic arterial pressure to below 60 mmHg was considered adequate. RVP was terminated when the balloon was adequately deflated. The MAP was stabilized post-RVP with bolus doses of epinephrine in 5-g steps; if the patient lost the sinus rhythm post-RVP, then the external pacemaker was used to achieve a stable ventricular rhythm. CPB was started if more than 10 bolus doses of epinephrine were necessary without an increase in the MAP or with persistent ventricular fibrillation. Figure 1 shows a typical time course of RVP.
• TEE monitoring: presurgical TEE evaluation was performed after induction of anesthesia in the operating room by the anesthesiologist. The entire TA-AVI procedure was monitored by TEE using the midesophageal long-axis view and the midesophageal shortaxis view to assess valve position and function. In addition to standard measurements, determination of the aortic annulus diameter was essential for valve size selection. 15 The aortic annulus diameter was measured repeatedly (3-5ϫ) using the midesophageal long-axis view in midsystole to evaluate correct valve sizing. The measurements were performed from the hinge point of the left or noncoronary cusp to the hinge point of the right coronary cusp, including aortic valve cusp calcification. Accurate measurement of the aortic annulus was vital. Based on the presurgical TEE measurements of the diameter of the aortic annulus, the size of the prosthesis was chosen. In order to achieve stable and safe positioning with low risk of paravalvular leakage, an oversizing technique of approximately 2 to 3 mm was used. Figure 2 shows the balloon valvuloplasty monitored in the midesophageal long-axis view during RVP.
• Postoperative course and analgesia: Postimplantation, the MAP was maintained above 65 mmHg; patients with stable postoperative hemodynamics were transferred to the postanesthetic care unit (PACU). If a patient required more than 3 g/kg/min of norepinephrine or epinephrine, they were transferred to the intensive care unit (ICU). In all patients, early extubation was attempted. For early postoperative analgesia, 1 g of acetaminophen was administered systemically before skin closure; in addition, local infiltration of the intercostal space was performed using 20 mL of ropivacaine (2 mg/mL). Further postoperative analgesia consisted of a bolus of piritramide (0.1 mg/kg) as required and acetaminophen (1 g every 6 hours) to achieve a pain score between 2 to 4 on an analog pain scale from 0 to 10. Variances of MAP during different time points were analyzed with repeated-measurement ANOVA. Contrasts between time points were estimated in case of global significance. The authors were particularly interested in the differences between the MAP values obtained pre-and postvalvuloplasty, pre-and postimplantation, and prevalvuloplasty and recovery. The time points for prevalvuloplasty and preimplantation were the MAP before RVP was started for valvuloplasty and preimplantation. For the postvalvuloplasty and postimplantation, the authors measured the MAP straight after the postvalvuloplasty and postimplantation. Recovery was the MAP 5 minutes after implantation of the valve but still under general anesthesia. The authors adjusted p values for 3 comparisons using Bonferroni correction. A probability of p Ͻ 0.05 was considered significant. All calculations were performed by using SPSS version 15.0 (SPSS Inc, Chicago, IL).
RESULTS
A total of 100 patients with significant AS received TA-AVI between February 2006 and January 2008. Table 1 shows anesthesia-related demographics. TA-AVI was performed completely off-pump in 81 patients. Table 2 shows the pre-and postoperative parameters of these 81 patients. There was no significant difference in the left ventricular function between preand postoperative measurements (56.2% Ϯ 14.1% v 55.8% Ϯ
Fig 2. Balloon valvuloplasty shown in the midesophageal long-axis view. Circle shows the balloon during rapid ventricular pacing (RVP).
3 ANESTHESIA AND TA-AVI 13.9%, not significant). Figure 3 shows changes in MAP in these 81 patients during the different phases of the procedure. There was a significant decline in MAP from pre-to postvalvuloplasty (74.7 Ϯ 9.1 mmHg v 63.6 Ϯ 11.3 mmHg, respectively) and from pre-to postimplantation (76.5 Ϯ 12.6 mmHg v 67.2 Ϯ 12.7, respectively). An increase in MAP from prevalvuloplasty to recovery (74.7 Ϯ 9.1 mmHg v 79.9 Ϯ 11.7 mmHg, respectively) also was seen. Table 3 shows the inotropic support for RVP prevalvuloplasty, preimplantation, and during recovery. After RVP, 3 patients required defibrillation: 2 after balloon valvuloplasty and 1 after valve implantation. Eleven patients (13.6%) were transferred to the postoperative unit with a paced rhythm. Fifty-four of the 81 patients were transferred to the PACU, whereas 27 patients were transferred to the ICU. The mean length of stay in the PACU was 3.6 Ϯ 1.4 hours, whereas in the ICU it was 21.2 Ϯ 11.1 hours. The time to extubation in the PACU was 1.4 Ϯ 1.1 hours v 9.3 Ϯ 6.8 hours in the ICU. The mean length of stay in the PACU was 5.5 Ϯ 2.3 hours versus 100.8 Ϯ 131.8 hours in the ICU.
In 19 patients, TA-AVI was performed on CPB for several reasons. The first 10 patients underwent TA-AVI with CPB at the beginning of the study series. This was done to ensure the safety and feasibility of TA-AVI. In 9 patients, CPB was rapidly required after RVP. After valve implantation, 8 patients required CPB and 1 patient required CPB after balloon dilatation because of hemodynamic deterioration. The MAP for these 9 patients immediately before hemodynamic deterioration was 70 Ϯ 15.3 mmHg. Norepinephrine support was needed in 4 patients (4.5 Ϯ 3.7 g/kg/min), epinephrine support was needed in 2 patients (2.5 Ϯ 0.7 g/kg/min), and 6 patients needed both norepinephrine (6.8 Ϯ 8.2 g/kg/min) and epinephrine infusions (8.3 Ϯ 7.0 g/kg/min). Of the 19 patients requiring CPB, 16 (84.2%) were transferred to the ICU and 3 (15.8%) were transferred to the PACU. The mean length of stay in the PACU was 5.5 Ϯ 2.3 hours and 100.8 Ϯ 131.8 hours in the ICU. The time to extubation in the PACU was 1.4 Ϯ 0.7 hours and 32.9 Ϯ 58.6 hours in the ICU. In the postoperative period, continuous inotropic support was necessary in 12 patients (63.2%). Intra-aortic balloon pump insertion was necessary in 5 patients, and 1 patient was transferred to the ICU with extracorporeal membrane oxygenation. These patients required 4.2 Ϯ 2.1 U of red blood cells. The cell saver was used in 3 patients. The volume of conserved blood was 790 Ϯ 666 mL. Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disorder. 
DISCUSSION
The goal of the minimally invasive TA-AVI is to decrease the invasiveness of the current gold standard, conventional AVR surgery, while maintaining excellent long-term results [16] [17] [18] by taking advantage of recent technical developments in the field of transcatheter aortic valve implantation. TA-AVI requires general anesthesia for the various steps of the surgical procedure. There are several considerations during this procedure that are of special interest for the anesthesiologist.
The avoidance of CPB and sternotomy, as well as the possibility to perform this procedure with a beating heart, may benefit elderly and high-risk patients. The inclusion criteria were patient age Ն75 years and a numeric EuroSCORE Ն9 points for this study; because of this high risk profile, the aim of the preoperative assessment was to identify the comorbidities and determine the anesthetic plan. All patients needed presurgical TEE investigation to measure the size of the aortic annulus so the valve could be sized to ensure firm, safe, and stable placement while decreasing the incidence of perivalvular leak. The authors also used the presurgical TEE to assess left ventricular function and volume status preoperatively. Using the TEE findings, regarding left ventricular function the authors selected the inotropes for hemodynamic management.
Another major issue for the anesthesia management of patients with AS is to ensure sufficient preload and perfusion of the hypertrophied ventricle. Volume loading was initiated using crystalloids before induction and controlled by the CVP as well as the TEE findings. The MAP was maintained above 65 mmHg. If this was not possible with volume alone, then inotropic support was given. If there were no RWMAs and preserved left ventricular function, the authors used bolus doses of 5 g of norepinephrine. In patients with any RWMAs or impaired left ventricular function, 5 g of epinephrine was used.
During the entire procedure, the anesthesiologist must be prepared for sudden hemodynamic deterioration, which may require inotropic support, ventricular pacing, or emergency CPB. The room setup for the TA-AVI must include the ability to go on to CPB as an emergency. This was needed in 9 patients.
The 2 short phases of RVP need special attention from the anesthesiologist, cardiologist, and surgeon. Arbitrarily, the authors chose a higher MAP (ie, 75 mmHg) before RVP, and it seemed to be sufficient based on the authors' experience. The significant decline in MAP seen post-RVP for both balloon valvuloplasty and valve implantation dictated the increase in MAP before RVP (Fig 3) . A possible cause for requiring CPB in the 9 patients might have been because of the inability to achieve a MAP above 75 mmHg just before starting RVP.
Ventricular fibrillation may occur after RVP; therefore, all patients must be connected reliably to the external defibrillator and the contact must be tested. Only 2 cases of persistent ventricular fibrillation after RVP were seen in this series. RVP is widely used for procedures other than TA-AVI. [19] [20] [21] An RVP of 180 beats/min was sufficient in this study, whereas Webb et al 22 and Ree et al 11 reported rates between 150 and 220 beats/ min of RVP for the transfemoral approach. The reason for higher rates for the transfemoral approach, in comparison to the TA-AVI, may be because of higher forces in the aorta for the retrograde, transfemoral technique in comparison to the antegrade, transapical approach. The balloon can be safely inflated to prevent sudden cardiac decompensation with occlusion of the left ventricular outflow tract only when reliable RVP capture associated with a marked reduction in systemic arterial pressure is obtained.
Ender et al 13 and Hemmerling et al 23 showed that fast-track anesthesia is favorable for the cardiac surgical patient. The present patients were treated following the authors' established fast-track protocol. Ender et al 13 showed a significantly lower incidence of postoperative low-cardiac-output syndrome and mortality in the fast-track group. This supports the authors' opinion that fast-track anesthesia is especially important for this group of patients. Fifty-four of the 81 patients who had off-pump operations could be managed in the PACU. They also had a significantly shorter time to extubation compared with patients who were treated in the ICU. Early extubation should be attempted, passive hypothermia must be avoided, and postoperative analgesia must be sufficient to support early postoperative mobilization.
The authors believe that the present data show that a thorough understanding of the anesthesia management, the surgical procedure, and the hemodynamic effects of RVP are required to ensure successful outcomes in this new surgical option for high-risk patients.
